# Metagenomi Therapeutics, Inc. (MGX)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/metagenomi-therapeutics-inc/ JSON: https://steadybase.io/company/metagenomi-therapeutics-inc.json Checked Nov 10, 2026. Latest filing read: Aug 10, 2026.

## Company

- Legal name: Metagenomi Therapeutics, Inc.
- Ticker: MGX (Nasdaq)
- SEC CIK: 0001785279
- Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
- Headquarters: Emeryville, CA
- Fiscal year ends: December 31
- SEC filer category: <br>Emerging growth company
- Website: metagenomi.co
- LinkedIn: https://www.linkedin.com/company/metagenomi
- Next earnings date: Nov 10, 2026

## Key facts

- Revenue: $25.2M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/0001193125-26-093976-index.html
- Operating income: -$96.0M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/0001193125-26-093976-index.html
- Net income: -$87.9M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/0001193125-26-093976-index.html
- SG&A: $26.8M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/0001193125-26-093976-index.html
- Employees: 119 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm
- Shares outstanding: 37,777,105 as of Aug 6, 2026 (10-Q filed Aug 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526342400/0001193125-26-342400-index.html
- Auditor: Pricewaterhousecoopers LLP, San Jose, California, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm

## Business

We are an in vivo genome editing company capitalizing on our proprietary technologies to create curative genetic medicines for patients. We were founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel gene editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. We leverage machine learning and artificial intelligence to enhance our signature gene editing systems.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $25.2M | -$96.0M | -$87.9M | $26.8M |
| Dec 31, 2024 | $52.3M | -$88.9M | -$78.1M | $32.0M |
| Dec 31, 2023 | $44.8M | -$78.5M | -$68.3M | $28.8M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/metagenomi-therapeutics-inc.json

## Officers and directors

- Jian Irish, President and Chief Executive Officer. Source: 10-K filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm
- Pamela Wapnick, Chief Financial Officer. Source: Form 4 filed Sep 10, 2026, https://www.sec.gov/Archives/edgar/data/1785279/000119312526387786/0001193125-26-387786-index.htm
- Willard Dere, Director, Chairman of the Board. Source: 10-K filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm
- Eric Bjerkholt, M.B.A., Class II Directors. Source: 8-K filed Jun 10, 2026, https://www.sec.gov/Archives/edgar/data/1785279/000119312526264392/mgx-20260609.htm
- Juergen Eckhardt, M.D., M.B.A., Class II Directors. Source: 8-K filed Jun 10, 2026, https://www.sec.gov/Archives/edgar/data/1785279/000119312526264392/mgx-20260609.htm
- Brian C. Thomas, Director. Source: 10-K filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm
- Eric Bjerkholt, Director. Source: 10-K filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm
- Juergen Eckhardt, Director. Source: 10-K filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm
- Laurence Reid, Director. Source: 10-K filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm
- Jian Irish, Ph.D., M.B.A., Board member (per proxy). Source: DEF 14A filed Apr 27, 2026, https://www.sec.gov/Archives/edgar/data/1785279/000119312526182325/mgx-20260421.htm
- Matthew L. Wein, J.D., Named in proxy. Source: DEF 14A filed Apr 27, 2026, https://www.sec.gov/Archives/edgar/data/1785279/000119312526182325/mgx-20260421.htm
- Pamela Wapnick, M.B.A., Named in proxy. LinkedIn: https://www.linkedin.com/in/pamela-wapnick-a980b1112. Source: DEF 14A filed Apr 27, 2026, https://www.sec.gov/Archives/edgar/data/1785279/000119312526182325/mgx-20260421.htm
- Willard H. Dere, M.D., Board member (per proxy). Source: DEF 14A filed Apr 27, 2026, https://www.sec.gov/Archives/edgar/data/1785279/000119312526182325/mgx-20260421.htm

## Recent 8-K events

- Sep 22, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526397037/mgx-20260921.htm
- Aug 10, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526342388/mgx-20260810.htm
- Jun 10, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526264392/mgx-20260609.htm
- May 11, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526216763/mgx-20260511.htm
- Mar 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093943/mgx-20260305.htm
- Jan 12, 2026: Item 5.03, Amendments to articles or bylaws; change in fiscal year; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526009928/mgx-20260112.htm
- Nov 12, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312525276135/mgx-20251111.htm
- Oct 1, 2025: Item 1.01, Entry into a material definitive agreement; Item 1.02, Termination of a material definitive agreement. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312525226878/mgx-20250929.htm
- Aug 12, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1785279/000095017025107304/mgx-20250812.htm
- Jun 11, 2025: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1785279/000095017025084529/mgx-20250610.htm

## Insider trades (Form 4)

- Sep 9, 2026: Laurence Reid (Director) bought 20,000 shares, about $23,401. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526389550/0001193125-26-389550-index.htm
- Sep 8, 2026: Matthew Wein (See Remarks) sold 358 shares, about $415. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526387816/0001193125-26-387816-index.htm
- Sep 8, 2026: Jian Irish (See Remarks) sold 2,140 shares, about $2,482. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526387798/0001193125-26-387798-index.htm
- Sep 8, 2026: Pamela Wapnick (Chief Financial Officer) sold 1,911 shares, about $2,217. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526387786/0001193125-26-387786-index.htm
- Jun 5, 2026: Pamela Wapnick (Chief Financial Officer) sold 2,884 shares, about $3,749. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526265335/0001193125-26-265335-index.htm
- Jun 5, 2026: Jian Irish (See Remarks) sold 3,737 shares, about $4,858. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526265332/0001193125-26-265332-index.htm
- Jun 5, 2026: Matthew Wein (See Remarks) sold 558 shares, about $725. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526265326/0001193125-26-265326-index.htm
- Mar 5, 2026: Pamela Wapnick (Chief Financial Officer) sold 1,581 shares, about $2,530. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526098824/0001193125-26-098824-index.htm
- Mar 5, 2026: Matthew Wein (See Remarks) sold 482 shares, about $771. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526098821/0001193125-26-098821-index.htm
- Mar 5, 2026: Jian Irish (Chief Executive Officer) sold 1,607 shares, about $2,571. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526098820/0001193125-26-098820-index.htm
- Dec 5, 2025: Brian C. Thomas (Director) sold 3,830 shares, about $6,779. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312525310971/0001193125-25-310971-index.htm
- Dec 5, 2025: Matthew Wein (See Remarks) sold 199 shares, about $352. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312525310958/0001193125-25-310958-index.htm
- Dec 5, 2025: Pamela Wapnick (Chief Financial Officer) sold 1,576 shares, about $2,790. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312525310953/0001193125-25-310953-index.htm
- Dec 5, 2025: Jian Irish (Chief Executive Officer) sold 1,602 shares, about $2,836. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312525310937/0001193125-25-310937-index.htm
- Sep 5, 2025: Brian C. Thomas (Director) sold 2,701 shares, about $4,889. Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312525304221/0001193125-25-304221-index.htm

## Latest filings

- 8-K filed Sep 22, 2026: https://www.sec.gov/Archives/edgar/data/1785279/000119312526397037/mgx-20260921.htm
- 10-K filed Mar 5, 2026: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm
- 10-Q filed Aug 10, 2026: https://www.sec.gov/Archives/edgar/data/1785279/000119312526342400/mgx-20260630.htm
- DEF 14A filed Apr 27, 2026: https://www.sec.gov/Archives/edgar/data/1785279/000119312526182325/mgx-20260421.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/